Cargando…

Body composition, resting energy expenditure and inflammatory markers: impact in users of depot medroxyprogesterone acetate after 12 months follow-up

OBJECTIVE: The aim of this study was to evaluate for 12 months the changes of body weight using Depot Medroxyprogesterone Acetate (DMPA) and if these changes are related to inflammatory markers. SUBJECTS AND METHODS: Twenty women of childbearing age who chose the DMPA, without previous use of this m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batista, Gisele Almeida, de Souza, Aglécio Luiz, Marin, Daniela Miguel, Sider, Marina, Melhado, Vaneska Carvalho, Fernandes, Arlete Maria, Alegre, Sarah Monte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522120/ https://www.ncbi.nlm.nih.gov/pubmed/27598979 http://dx.doi.org/10.1590/2359-3997000000202

Ejemplares similares

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020)

An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract
por: Ayele, Hossaena, et al.
Publicado: (2021)

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate
por: Bradley, Frideborg, et al.
Publicado: (2022)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
por: Walker, Christie, et al.
Publicado: (2013)

Successful treatment of Depot Medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in Adolescents
por: Rager, Kristin M., et al.
Publicado: (2006)

Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility
por: Smith-McCune, K K, et al.
Publicado: (2017)

Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
por: Yang, Liying, et al.
Publicado: (2019)

Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections
por: Dabee, Smritee, et al.
Publicado: (2023)

What Distinguishes Women Who Choose to Self-Inject? A Prospective Cohort Study of Subcutaneous Depot Medroxyprogesterone Acetate Users in Ghana
por: Nai, Dela, et al.
Publicado: (2022)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model
por: Curry, Leslie, et al.
Publicado: (2013)

Protective Effect of Vitamins C and E on Depot-Medroxyprogesterone Acetate-Induced Ovarian Oxidative Stress In Vivo
por: Ismiyati, Atik, et al.
Publicado: (2016)

Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial()()()()
por: Chinula, Lameck, et al.
Publicado: (2018)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices
por: Birse, Kenzie D., et al.
Publicado: (2017)

Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression
por: Morrison, Charles S., et al.
Publicado: (2020)

Exploring the immunomodulatory role of depot medroxyprogesterones acetate and endogenous progesterone levels in HIV infected and uninfected women
por: Mnqonywa, Nonzwakazi, et al.
Publicado: (2019)

Changes in key vaginal bacteria among postpartum African women initiating intramuscular depot-medroxyprogesterone acetate
por: Whitney, Bridget M., et al.
Publicado: (2020)

Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
por: Wessels, Jocelyn M., et al.
Publicado: (2021)

A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment
por: Francis, Jose, et al.
Publicado: (2021)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

Adolescent and covert family planning users’ experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate
por: Burke, Holly M., et al.
Publicado: (2020)

High dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate
por: Emilda, A S, et al.
Publicado: (2016)

A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017)

Prevalence of Documented Excessive Weight Gain Among Adolescent Girls and Young Women Using Depot Medroxyprogesterone Acetate
por: Jirakittidul, Preeyaporn, et al.
Publicado: (2019)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()
por: Smith, Tiffany Joyce, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8r897113043b8378a99ceu9io7